Telomir Pharmaceuticals, Inc. - Common Stock (TELO)
1.2400
+0.00 (0.00%)
NASDAQ · Last Trade: Sep 6th, 7:27 PM EDT
Detailed Quote
Previous Close | 1.240 |
---|---|
Open | 1.240 |
Bid | 1.220 |
Ask | 1.250 |
Day's Range | 1.220 - 1.280 |
52 Week Range | 1.120 - 8.400 |
Volume | 348,341 |
Market Cap | 40.03M |
PE Ratio (TTM) | 1.348 |
EPS (TTM) | 0.9 |
Dividend & Yield | N/A (N/A) |
1 Month Average Volume | 3,927,698 |
Chart
About Telomir Pharmaceuticals, Inc. - Common Stock (TELO)
Telomir Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative therapies that target cellular aging and age-related diseases. The company specializes in the research and development of medications aimed at enhancing telomere function, which plays a crucial role in cellular health and longevity. By leveraging advanced scientific insights, Telomir Pharmaceuticals aims to transform the treatment landscape for conditions such as cancer and degenerative diseases, ultimately striving to improve the quality of life for patients by addressing the underlying mechanisms of aging. Read More
News & Press Releases
Via Benzinga · August 29, 2025
Via Benzinga · August 28, 2025
Let's have a look at what is happening on the US markets after the closing bell on Thursday. Below you can find the top gainers and losers in today's after hours session.
Via Chartmill · August 28, 2025
The market is filled with gapping stocks in Thursday's session. Let's discover which stocks are showing gap-ups and gap-downs.
Via Chartmill · August 28, 2025
Before the opening bell on Thursday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session.
Via Chartmill · August 28, 2025
Via Benzinga · August 28, 2025
In vitro findings reveal Telomir-1's dual action: targeting DNA methylation switches and cutting into the Wnt "fuel line" that drives cancer growth.
Via ACCESS Newswire · August 28, 2025
U.S. stock futures were swinging on Thursday following Wednesday's advances. Futures of major benchmark indices were largely mixed.
Via Benzinga · August 28, 2025
Via Benzinga · August 28, 2025
Telomir Pharmaceuticals' shares jumped 35% after promising data showed its lead drug Telomir-1 may offer a safer, dual-action treatment for cancer and aging-related diseases.
Via Benzinga · August 28, 2025
Via Benzinga · August 27, 2025
Discover the top movers in Wednesday's after-hours session and stay informed about the post-market dynamics.
Via Chartmill · August 27, 2025
New data from Eurofins Discovery show that Telomir-1 blocks enzymes that drive disease by turning off critical genes-highlighting its potential to treat cancer, autoimmune conditions, neurodegeneration, and metabolic disorders through epigenetic modulation.
Via ACCESS Newswire · August 7, 2025
This unique cellular activity may help restore energy balance and improve essential cell functions such as protein synthesis and membrane stability in diseases like Parkinson's ALS Alzheimer's and Progeria where mitochondrial failure and oxidative stress drive progression
Via ACCESS Newswire · July 24, 2025
As we await the opening of the US market on Monday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
Via Chartmill · July 21, 2025
Via Benzinga · July 21, 2025
Via Benzinga · July 21, 2025
Wondering how the US markets performed one hour before the close of the markets on Friday? Discover the movers and shakers of today's session in our comprehensive analysis.
Via Chartmill · July 18, 2025
Discover the most active stocks in Friday's session. Stay informed about the stocks that are generating the most trading volume!
Via Chartmill · July 18, 2025
On Friday, there are stocks with unusual volume. Let's take a look.
Via Chartmill · July 18, 2025
Curious about what's happening in today's session? Check out the latest stock movements and price changes.
Via Chartmill · July 18, 2025
Today's session on Friday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.
Via Chartmill · July 18, 2025